Evaluation of the use of Lactobacilli for gum treatment in patients with Diabetes
- Conditions
- Bacterial infections and mycosesChronic PeriodontitisDiabetes Mellitus, Type 2E00-E90
- Registration Number
- RBR-8t4qqx
- Lead Sponsor
- niversidade Estadual Paulista Júlio de Mesquita Filho
- Brief Summary
Aim: Subgingival instrumentation with probiotics may be a proposal for the treatment of periodontitis (P), especially for patients with type 2 Diabetes Mellitus (T2DM). The Lactobacillus reuteri probiotic as an adjunctive therapy in the treatment of P associated with T2DM were evaluated. Materials and Methods: Forty diabetic participants diagnosed with P (Stage III and IV, Grade B), were randomized into SRP+Placebo (n=20): subgingival instrumentation plus placebo lozenges and SRP+Probi (n=20): subgingival instrumentation plus probiotics. Probing depth (PD), gingival recession (GR), clinical attachment level (CAL), plaque index (PI), bleeding on probing (BoP) and PISA index were performed at baseline, 30, 90 and 180 days. Cytokines concentration in the gingival crevicular fluid, subgingival biofilm sample and LDL and HDL subfractions were evaluated. Results: Subgingival instrumentation improved the clinical periodontal parameters in both groups (p<0.05), the PISA index and interfered in the cytokine levels. There was a reduction in all microbial complexes. SRP+Probi showed a better result in the LDL and HDL subfractions. Conclusion: Subgingival instrumentation improved the clinical periodontal parameters in patients with T2DM. The use of L. reuteri probiotics had no additional effects compared with the placebo, however, there was a positive effect on the lipoprotein subfraction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Individuals over 35 years old; patients with type 2 diabetes mellitus; carriers of generalized chronic periodontitis; present at least 16 teeth; agree to participate in the study and sign the informed consent form for participation in the research
Patients with cardiovascular disease, cancer, gastrointestinal disorders, skin diseases, pregnancy, lactation, smoking, arthritis, lupus; have undergone periodontal treatment in the last 12 months; have made use of antioxidant, anti-inflammatory, or antibiotic supplements within the previous 3 months; have changed the blood glucose control medication in the last 3 months; present dental elements with pulp or periapical inflammation; have any other diseases of inflammatory origin
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected outcome 1: It was expected to find a greater reduction in the pocket depth measured, the primary variable of the study, in the group with adjuvant therapy with the probiotic, verified through clinical periodontal examination. It was also expected to assess the response of inflammatory mediators and the lipid and microbiological profile to the applied intervention.;Outcome found 1: Through the clinical examination, there was a reduction in probing depth in both groups, a reduction in the amount of periodontopathogenic bacteria in periodontal pockets and a change in the lipid profile of the probiotic group.
- Secondary Outcome Measures
Name Time Method Secondary outcomes were not expected.